arrow
A

Aziz Zaanan

paris-cité university
H指数:41
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

奥昔帕利单抗和替雷利珠单抗在晚期食管鳞状细胞癌中的应用(AdvanTIG-203):一项II期研究

2026-09-180
OAAI
Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study

帕博利珠单抗作为局部dMMR/MSI食管胃癌的新辅助治疗是否安全有效?——IMHOTEP II期研究的结果

2026-09-090
OAAI
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: a retrospective study by AGEO

靶向疗法治疗转移性小肠腺癌的疗效:AGEO进行的一项回顾性研究

2026-03-280
PRE
Gastric cancer: French Intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)

胃癌:法国多中心临床实践指南用于诊断、分期、治疗和随访(TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)

2026-03-240
OAAI
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

一线zolbetuximab联合mFOLFOX6和nivolumab治疗不可切除的CLDN18.2阳性胃或胃食管结合部腺癌:一项Ⅱ期临床试验

2026-03-160
OAAI
Plasma Protein Biomarkers to Detect Early Gastric Preneoplasia and Cancer: A Prospective Study

血浆蛋白生物标志物检测早期胃前癌和癌症:一项前瞻性研究

2026-03-030
OAAI
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study

循环肿瘤DNA驱动抗EGFR再挑战疗法在转移性结直肠癌中的应用:RASINTRO前瞻性多中心研究

2025-09-010
PRE
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study

局部晚期可切除胃或胃食管结合部腺癌治疗期间纵向循环肿瘤DNA分析:PLAGAST前瞻性生物标志物研究

2025-07-240
OAAI
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

循环肿瘤DNA强烈预测化疗联合免疫检查点抑制剂在晚期胃食管腺癌患者中的疗效

2025-04-240
OA
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

TFOX与FOLFOX在HER2阴性晚期胃或胃食管结合部腺癌患者一线治疗中的比较(PRODIGE 51-FFCD-GASTFOX):一项开放标签、多中心、随机、III期临床试验

2025-04-230
PRE
PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA:一项II期随机试验,旨在评估mFOLFIRINOX和mFOLFOX方案在局部晚期或转移性小肠腺癌治疗中的效果。

2024-09-010
PRE
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Nal-IRI/LV5-FU 与 paclitaxel 作为转移性食管鳞状细胞癌患者二线治疗的比较(OESIRI-PRODIGE 62):一项 FFCD 多中心、随机、II 期研究

2024-09-010
PRE
Trifluridine/tipiracil plus oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
2024-08-010
OAAI
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
2024-05-142
PRE